In addition, METTL3‐depleted pancreatic cancer cells showed higher sensitivity to anticancer reagents such as gemcitabine, 5‐fluorouracil, cisplatin and irradiation, suggesting that METTL3 is a potent target for enhancing therapeutic efficacy.19 This evidence concerns the gene METTL3 and familial pancreatic carcinoma.